93 Shennecossett Rd.
Groton, CT 06340
Virtus Therapeutics (C-corp) is focused on the development of the first treatment for pantothenate kinase-associated neurodegeneration (PKAN) using small molecule activators.
– Evaluate the activity of VTACs in cell-based assays
– Select advanced derivatives of VTACs using biochemical, structural and cell biological assays.
– Evaluate the activity of VTACs in animal models of PKAN